Class information for:
Level 1: ANDROGEN DEPRIVATION THERAPY//BICALUTAMIDE//COMBINED ANDROGEN BLOCKADE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
1816 2475 32.6 72%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
21 4 UROLOGY & NEPHROLOGY//UROL//JOURNAL OF UROLOGY 229838
272 3       PROSTATE CANCER//PROSTATIC NEOPLASMS//UROL 43768
534 2             ANDROGEN RECEPTOR//PROSTATE CANCER//CASTRATION RESISTANT PROSTATE CANCER 14838
1816 1                   ANDROGEN DEPRIVATION THERAPY//BICALUTAMIDE//COMBINED ANDROGEN BLOCKADE 2475

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ANDROGEN DEPRIVATION THERAPY authKW 1366358 11% 41% 270
2 BICALUTAMIDE authKW 521591 4% 41% 102
3 COMBINED ANDROGEN BLOCKADE authKW 424174 2% 72% 48
4 INTERMITTENT ANDROGEN SUPPRESSION authKW 407429 1% 97% 34
5 ANDROGEN ANTAGONISTS authKW 350325 2% 47% 61
6 DEGARELIX authKW 347530 1% 78% 36
7 PROSTATE CANCER authKW 283294 32% 3% 783
8 ANDROGEN DEPRIVATION authKW 255841 3% 25% 83
9 LHRH AGONIST authKW 235004 2% 39% 49
10 ANTIANDROGEN authKW 229538 4% 17% 109

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Urology & Nephrology 81975 53% 1% 1307
2 Oncology 5823 26% 0% 650
3 Andrology 1452 2% 0% 39
4 Endocrinology & Metabolism 1303 10% 0% 246
5 Pharmacology & Pharmacy 159 7% 0% 183
6 Medicine, General & Internal 121 5% 0% 124
7 Health Care Sciences & Services 23 1% 0% 27
8 Geriatrics & Gerontology 20 1% 0% 19
9 Nursing 6 1% 0% 15
10 Toxicology 3 1% 0% 29

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 UROL 65863 31% 1% 767
2 STRATEG INVEST COMPREHENS CANC NETWORK 31212 0% 28% 9
3 WARD 14 27754 0% 75% 3
4 INTEGRAT CANC THER Y UROL 25105 1% 11% 18
5 UROEVIDENCE 22202 0% 60% 3
6 J ANESE UROL ASSOC 16446 0% 67% 2
7 GERIATR PROGRAM 13307 0% 10% 11
8 ABT GASTROENTEROL ENDOKRINOL ZENTRUM INNERE MED 12336 0% 100% 1
9 AKKREDITIERTES ZWEITMEINUNGSZENTRUM KEIMZELLTUMOR 12336 0% 100% 1
10 AMER FDN UROL DIS PROSTATE QUAL ENHANCEMENT 12336 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PROSTATE CANCER AND PROSTATIC DISEASES 51290 3% 6% 67
2 EUROPEAN UROLOGY SUPPLEMENTS 46415 2% 8% 47
3 EUROPEAN UROLOGY 40003 6% 2% 153
4 UROLOGY 25542 7% 1% 184
5 BJU INTERNATIONAL 22481 5% 2% 122
6 PROSTATE 16005 3% 2% 77
7 JOURNAL OF UROLOGY 14698 7% 1% 183
8 MOLECULAR UROLOGY 7030 0% 6% 10
9 PROGRES EN UROLOGIE 6574 2% 1% 42
10 BRITISH JOURNAL OF UROLOGY 5261 2% 1% 51

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 ANDROGEN DEPRIVATION THERAPY 1366358 11% 41% 270 Search ANDROGEN+DEPRIVATION+THERAPY Search ANDROGEN+DEPRIVATION+THERAPY
2 BICALUTAMIDE 521591 4% 41% 102 Search BICALUTAMIDE Search BICALUTAMIDE
3 COMBINED ANDROGEN BLOCKADE 424174 2% 72% 48 Search COMBINED+ANDROGEN+BLOCKADE Search COMBINED+ANDROGEN+BLOCKADE
4 INTERMITTENT ANDROGEN SUPPRESSION 407429 1% 97% 34 Search INTERMITTENT+ANDROGEN+SUPPRESSION Search INTERMITTENT+ANDROGEN+SUPPRESSION
5 ANDROGEN ANTAGONISTS 350325 2% 47% 61 Search ANDROGEN+ANTAGONISTS Search ANDROGEN+ANTAGONISTS
6 DEGARELIX 347530 1% 78% 36 Search DEGARELIX Search DEGARELIX
7 PROSTATE CANCER 283294 32% 3% 783 Search PROSTATE+CANCER Search PROSTATE+CANCER
8 ANDROGEN DEPRIVATION 255841 3% 25% 83 Search ANDROGEN+DEPRIVATION Search ANDROGEN+DEPRIVATION
9 LHRH AGONIST 235004 2% 39% 49 Search LHRH+AGONIST Search LHRH+AGONIST
10 ANTIANDROGEN 229538 4% 17% 109 Search ANTIANDROGEN Search ANTIANDROGEN

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 NGUYEN, PL , ALIBHAI, SMH , BASARIA, S , D'AMICO, AV , KANTOFF, PW , KEATING, NL , PENSON, DF , ROSARIO, DJ , TOMBAL, B , SMITH, MR , (2015) ADVERSE EFFECTS OF ANDROGEN DEPRIVATION THERAPY AND STRATEGIES TO MITIGATE THEM.EUROPEAN UROLOGY. VOL. 67. ISSUE 5. P. 825 -836 65 63% 35
2 TROST, LW , SEREFOGLU, E , GOKCE, A , LINDER, BJ , SARTOR, AO , HELLSTROM, WJG , (2013) ANDROGEN DEPRIVATION THERAPY IMPACT ON QUALITY OF LIFE AND CARDIOVASCULAR HEALTH, MONITORING THERAPEUTIC REPLACEMENT.JOURNAL OF SEXUAL MEDICINE. VOL. 10. ISSUE . P. 84 -101 104 60% 8
3 KUNATH, F , GROBE, HR , RUCKER, G , MOTSCHALL, E , ANTES, G , DAHM, P , WULLICH, B , MEERPOHL, JJ , (2014) NON-STEROIDAL ANTIANDROGEN MONOTHERAPY COMPARED WITH LUTEINISING HORMONE-RELEASING HORMONE AGONISTS OR SURGICAL CASTRATION MONOTHERAPY FOR ADVANCED PROSTATE CANCER.COCHRANE DATABASE OF SYSTEMATIC REVIEWS. VOL. . ISSUE 6. P. - 86 64% 2
4 SHORE, ND , ABRAHAMSSON, PA , ANDERSON, J , CRAWFORD, ED , LANGE, P , (2013) NEW CONSIDERATIONS FOR ADT IN ADVANCED PROSTATE CANCER AND THE EMERGING ROLE OF GNRH ANTAGONISTS.PROSTATE CANCER AND PROSTATIC DISEASES. VOL. 16. ISSUE 1. P. 7-15 63 78% 15
5 SCHULMAN, CC , IRANI, J , MOROTE, J , SCHALKEN, JA , MONTORSI, F , CHLOSTA, PL , HEIDENREICH, A , (2010) ANDROGEN-DEPRIVATION THERAPY IN PROSTATE CANCER: A EUROPEAN EXPERT PANEL REVIEW.EUROPEAN UROLOGY SUPPLEMENTS. VOL. 9. ISSUE 7. P. 675 -691 75 74% 9
6 SHIOTA, M , ETO, M , (2016) CURRENT STATUS OF PRIMARY PHARMACOTHERAPY AND FUTURE PERSPECTIVES TOWARD UPFRONT THERAPY FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER.INTERNATIONAL JOURNAL OF UROLOGY. VOL. 23. ISSUE 5. P. 360 -369 59 59% 4
7 LIAW, BC , SHEVACH, J , OH, WK , (2015) SYSTEMIC THERAPY FOR THE TREATMENT OF HORMONE-SENSITIVE METASTATIC PROSTATE CANCER: FROM INTERMITTENT ANDROGEN DEPRIVATION THERAPY TO CHEMOTHERAPY.CURRENT UROLOGY REPORTS. VOL. 16. ISSUE 3. P. - 50 88% 2
8 ABRAHAMSSON, PA , (2010) POTENTIAL BENEFITS OF INTERMITTENT ANDROGEN SUPPRESSION THERAPY IN THE TREATMENT OF PROSTATE CANCER: A SYSTEMATIC REVIEW OF THE LITERATURE.EUROPEAN UROLOGY. VOL. 57. ISSUE 1. P. 49-59 41 95% 100
9 ALLAN, CA , COLLINS, VR , FRYDENBERG, M , MCLACHLAN, RI , MATTHIESSON, KL , (2014) ANDROGEN DEPRIVATION THERAPY COMPLICATIONS.ENDOCRINE-RELATED CANCER. VOL. 21. ISSUE 4. P. T119 -T129 59 70% 10
10 SINGER, EA , GOLIJANIN, DJ , MIYAMOTO, H , MESSING, EM , (2008) ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 9. ISSUE 2. P. 211-228 80 60% 20

Classes with closest relation at Level 1


Rank Class id link
1 1969 CABAZITAXEL//ABIRATERONE//CASTRATION RESISTANT PROSTATE CANCER
2 10053 WOMENS HOSP MAX PLANCK CLIN UNIT REPROD MED//ANIM SCI PROD GRP//1000 CARSON ST
3 26762 SELECTIVE ANDROGEN RECEPTOR MODULATOR//SARM//SARMS
4 894 PROSTATE CANCER//HYPOFRACTIONATION//INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
5 19561 FOSFESTROL//PROSTATE//AMYLOID PRECURSOR PROTEIN GENE APP
6 36524 4 NITRO3 TRIFLUOROMETHYLANILINE//AHND//ANTICANCER DRUG FLUTAMIDE
7 12558 UNIV INTEGRATED HOSP//PROSTATE CANCER//TOTAL TESTOSTERONE TT
8 538 RADICAL PROSTATECTOMY//PROSTATECTOMY//BIOCHEMICAL RECURRENCE
9 1876 ANDROGEN RECEPTOR//GEORGE WHIPPLE CANC//CASTRATION RESISTANT PROSTATE CANCER
10 21262 BONE SCAN INDEX//BONE SCAN//SKELETAL ALKALINE PHOSPHATASE

Go to start page